APA:
Copy. (2018). The recombinant human secretory leukocyte protease inhibitor (SLPI) protects cardiac fibroblasts injury against an in vitro ischemia/reperfusion injury. JAPS (JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE), 8(6), 156-162. SID. https://sid.ir/paper/737661/en
Vancouver:
Copy. The recombinant human secretory leukocyte protease inhibitor (SLPI) protects cardiac fibroblasts injury against an in vitro ischemia/reperfusion injury. JAPS (JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE)[Internet]. 2018;8(6):156-162. Available from: https://sid.ir/paper/737661/en
IEEE:
Copy, “The recombinant human secretory leukocyte protease inhibitor (SLPI) protects cardiac fibroblasts injury against an in vitro ischemia/reperfusion injury,” JAPS (JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE), vol. 8, no. 6, pp. 156–162, 2018, [Online]. Available: https://sid.ir/paper/737661/en